Highest-materiality recent filing
Reviva Q1 net loss $3.2M; stock moving from Nasdaq to OTCQB effective May 14
Net loss $3.2M ($0.46/share) vs $6.4M ($2.61) in Q1 2025; cash $22.2M up from $14.4M.
Reviva Pharmaceuticals to be delisted from Nasdaq May 14, 2026; will trade on OTCQB
Nasdaq Hearings Panel determined to delist RVPH due to non-compliance with minimum $1.00 bid price rule.
Reviva targets brilaroxazine patent extension to 2046, plans API switch in RECOVER-2 trial
Filed composition of matter patent on new brilaroxazine form; pursuing accelerated review to extend exclusivity potentially through 2046.
Reviva reports FY2025 net loss of $19.9M; FDA requires second Phase 3 trial for schizophrenia drug
Net loss of $19.9M ($5.48 per share) vs $29.9M ($17.73) in FY2024.
Reviva Pharmaceuticals announces $10M public offering of stock and warrants
Offering of 6,666,667 shares (or pre-funded warrants) plus Series G and H warrants at $1.50/unit; gross proceeds $10M.
Reviva Pharma announces 1:20 reverse stock split to regain Nasdaq minimum bid price compliance
Reverse stock split at 1:20 ratio effective 12:01 a.m. ET on March 9, 2026; no fractional shares, rounding up.
Reviva gets Nasdaq extension to March 27, 2026 for minimum bid price rule compliance
Nasdaq Panel granted exception through March 27, 2026 to regain compliance with $1.00 minimum bid price.
FDA recommends RECOVER-2 Phase 3 trial (30/50 mg) before NDA submission; similar to RECOVER design.
Reviva reports Q3 net loss of $4.0M; cash $13.2M; pre-NDA meeting with FDA on track
Net loss of $4.0M ($0.06 per share) for Q3 2025, compared to $8.4M ($0.25) in Q3 2024.
Reviva prices $9M public offering of 27M shares and warrants at $0.335/unit
27M shares of common stock plus Series E (5-year term) and Series F (1-year term) warrants, each exercisable for 27M shares at $0.335.
Reviva Q2 2025 net loss $6.1M ($0.12/share); cash $10.4M; brilaroxazine OLE data positive
Net loss $6.1M vs $7.9M YoY; cash $10.4M as of June 30, 2025, down from $13.5M at Dec 2024.
Reviva prices $10M public offering of 20M shares and warrants at $0.50 per unit
Offering comprises 20M shares, 20M Series C warrants (5-year, $0.50 exercise), and 20M Series D warrants (12-month, $0.50 exercise).
Reviva reports positive full dataset from Phase 3 OLE study of brilaroxazine in schizophrenia
Brilaroxazine showed sustained efficacy across all symptom domains: PANSS total score improved -18.1 at 12 months (p≤0.001).
Reviva Pharmaceuticals enters into ATM sales agreement for up to $50M common stock offering
On May 30, 2025, Reviva entered an ATM agreement with B. Riley Securities and Alliance Global Partners to sell up to $50M of common stock.
Reviva Q1 2025 net loss $6.4M; cash $5.3M; OLE trial complete with 446 patients
Net loss $6.4M ($0.13/sh) vs $7.4M ($0.25/sh) in Q1 2024; cash & equivalents $5.3M as of Mar 31, 2025 down from $13.5M at Dec 31, 2024.
Reviva reports FY2024 net loss $29.9M, cash $13.5M; positive OLE data sustained
Net loss $29.9M ($0.90/shr) vs $39.3M ($1.65/shr) in 2023; cash $13.5M at Dec 31, 2024 vs $23.4M.
Reviva reports positive preliminary 1-year OLE data for brilaroxazine in schizophrenia
435 patients enrolled in OLE; 113 completed 52 weeks; pooled PANSS total decreased 18.6 points (p≤0.0001).
Authorized common shares increased to 315M from 115M, effective December 10, 2024.
Reviva Q3 net loss $8.4M; 108 patients complete 1-year OLE trial for brilaroxazine
Net loss of $8.4M ($0.25/sh) for Q3 2024 vs $11.3M ($0.48/sh) in Q3 2023 (restated).
Reviva: 108 patients complete 1-year brilaroxazine OLE; topline data expected Dec 2024
108 patients completed 12-month treatment; over 250 completed 6 months in the OLE study.
Reviva Pharmaceuticals raises $3.8M net in public offering of common stock and warrants
Net proceeds from offering updated to $3.8M; closed Aug 22, 2024.
Reviva prices $5.0M at-the-market offering of common stock and warrants
Offering comprises 4,761,905 shares (or pre-funded warrants) plus warrants for same number; combined price $1.05 per unit.
Reviva Q2 2024 net loss $7.9M; cash $6.2M; OLE topline data expected Q4 2024
Net loss of $7.9M ($0.26/sh) vs $11.7M ($0.52/sh) in Q2 2023; six-month loss $15.3M ($0.51/sh).
358 patients enrolled; 223 currently on treatment across USA, Europe, and Asia.
Reviva Q1 net loss $7.4M; FDA alignment on brilaroxazine NDA path
Net loss approximately $7.4M ($0.25 per share) for Q1 2024 vs $6.9M ($0.31 per share) for Q1 2023.
Reviva Pharmaceuticals to restate 2022 and 2023 financials; R&D expenses understated by ~$3.9M
Audit Committee concluded prior financials for FY2022, Q3 2022, and all quarterly periods in FY2023 should no longer be relied upon due to errors in clinical trial expense accruals.
Net loss $39.3M ($1.65/sh) for FY2023 vs restated $28.3M ($1.45/sh) for FY2022.
Reviva gains FDA alignment on Phase 3 RECOVER-2 study for brilaroxazine in schizophrenia
FDA accepts 4-week RECOVER-2 study; two positive Phase 3 studies plus 12-month safety could support NDA.
Reviva raises $30M in registered direct offering of common stock and warrants
Offering of 5,853,660 shares (or pre-funded warrants) and 5,853,660 warrants at $5.125 per unit.
Reviva reports Q3 loss of $10.5M; Phase 3 brilaroxazine trial meets all endpoints
Phase 3 RECOVER trial met primary endpoint: 10.1-point PANSS reduction for 50 mg brilaroxazine vs placebo at week 4 (p<0.001).
Reviva announces positive Phase 3 RECOVER trial results for brilaroxazine in schizophrenia
Primary endpoint met: brilaroxazine 50 mg showed 10.1-point PANSS reduction vs placebo (p<0.001) at week 4.
Enrollment of 402 patients across US (~60%), Europe (~10%), and Asia (~30%) in pivotal Phase 3 RECOVER trial.
Reviva Q2 net loss $12.4M; cash $11.2M; Phase 3 schizophrenia data due Oct 2023
Net loss of $12.4M ($0.55 per share) for Q2 2023 vs $5.3M ($0.29) a year ago.
Reviva Pharmaceuticals: Phase 3 RECOVER study enrollment exceeds 80%; topline data expected Q3 2023
Over 80% of patients enrolled in pivotal Phase 3 RECOVER study of brilaroxazine for schizophrenia; enrollment ongoing in US, Europe, Asia.
Reviva Q1 net loss $6.6M; cash to fund ops through Q3 2023; Phase 3 topline data mid-2023
Net loss of $6.6M ($0.30/shr) vs $7.4M ($0.40) in Q1 2022; cash $11.3M at Mar 31, 2023, down from $18.5M.
Net loss of $24.3M ($1.25 per share) vs $8.5M ($0.58 per share) in FY2021.
Reviva reports 40% enrollment in Phase 3 schizophrenia trial; top-line data expected mid-2023
About 40% of patients treated in pivotal Phase 3 RECOVER trial of brilaroxazine; no treatment-related SAEs.
On June 23, 2022, Marc Cantillon, the Chief Medical Officer of Reviva Pharmaceuticals Holdings, Inc. (the “Company”), notified the Company that he will resign as Chief Medical Officer of the Company effective as of July 5, 2022 to pursue additional opportunities.
Max materiality 1.00 · Median 0.65 · Most common event other_material